A randomized phase II study of oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine (XELOX) in patients with advanced or recurrent colorectal cancer.

Trial Profile

A randomized phase II study of oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine (XELOX) in patients with advanced or recurrent colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2012

At a glance

  • Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 01 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jan 2012 Results presented at the 2012 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top